Fifth indication for seizure drug approved
Lamotrigine (Lamictal) has been approved for its fifth indication as an antiepileptic—this time as an add-on therapy to treat primary generalized tonic-clonic seizures in children two years of age and older and adults.
Lamotrigine (Lamictal) has been approved for its fifth indication as an antiepilepticthis time as an add-on therapy to treat primary generalized tonic-clonic seizures in children two years of age and older and adults. The drug is also approved as a maintenance treatment for bipolar I disorder in adults.
To see more Hot off the Press news articles, click here.
To go to the Drug Topics homepage, click here.
FDA’s Recent Exemptions: What Do They Mean as We Finalize DSCSA Implementation?
October 31st 2024Kala Shankle, Vice President of Regulatory Affairs with the Healthcare Distribution Alliance, and Ilisa Bernstein, President of Bernstein Rx Solutions, LLC, discussed recent developments regarding the Drug Supply Chain Security Act.
